- Home
- NXT vs MDGL Comparison
NXT vs MDGL Comparison
Compare NXT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXT | MDGL |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 12.8B |
| IPO Year | 2023 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NXT | MDGL |
|---|---|---|
| Price | $91.32 | $470.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 12 |
| Target Price | $115.67 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 3.0M | 354.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.66 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $3,559,390,000.00 | $180,133,000.00 |
| Revenue This Year | $19.76 | $58.39 |
| Revenue Next Year | $11.96 | $48.55 |
| P/E Ratio | $23.40 | ★ N/A |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $52.61 | $315.00 |
| 52 Week High | $163.13 | $615.00 |
Technical Indicators
Market Signals| Indicator | NXT | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 36.23 |
| Support Level | $84.48 | $457.52 |
| Resistance Level | $94.52 | $555.57 |
| Average True Range (ATR) | 6.21 | 23.74 |
| MACD | -0.89 | -9.47 |
| Stochastic Oscillator | 9.04 | 25.04 |
Price Performance
Historical ComparisonAbout NXT Nextracker Inc.
Nextpower (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextpower's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextpower has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.